As indicated by Koichi AKAISHI, Chief Policy officer of the Cabinet Office, the government’s new bio-strategy will include support of company investments in the following 10 areas:

(1) high-performance biomaterials

(2) bioplastics

(3) sustainable primary production systems (agriculture)

(4) organic waste and organic wastewater treatment

(5) life improvement, healthcare and functional food

(6) digital medicine

(7) bioproduction systems (medicine, regenerative medicine, cell and gene therapy)

(8) bioproduction system (industrial products)

(9) bioanalysis and research tools

(10) large-size wood buildings

There will be a roadmap for regulations, standards and standardization necessary for market creation in each area, to be published in December 2019.

Nikkei Biotech news release, May 31, 2019